Skip to main content
main-content

Medicine Matters rheumatology

Therapeutic class

Therapeutic target

Drug name

Phase/ status

Trial ID

B-cell therapy








CD20




Obintuzumab

Phase II- recruitment completed

NCT02550652

Ocrelizumab

Phase III- terminated due to adverse effect of infection

NCT00626197 BELONG

Rituximab

Phase III- completed

NCT00282346 LUNAR

CD20 & BLyS/BAFF

Rituximab followed by belimumab

Phase II- recruited completed

NCT02260934 CALIBRATE

BLyS/BAFF

Belimumab

Phase III- recruitment completed

NCT01639339 BLISS-LN

Proteasome inhibitor



Ixazomib

Phase I- terminated; insufficient enrollment

NCT02176486

KZR-616

Phase I, II- recruiting

NCT03393013

T-cell therapy






Calcineurin inhibitors



Voclosporin

Phase III- recruitment completed

NCT03021499 AURORA

Tacrolimus


Phase IV- completed

NCT00371319

n/a

NCT00876616

CD28- CD80/86



Abatacept



Phase II- completed

NCT00774852 ACCESS

Phase II/III- completed

NCT00430677

Phase III- completed

NCT01714817

CD40



CFZ533

Phase II- recruiting

NCT03610516

BI 655064

Phase II- recruiting

NCT03385564

Interferon inhibition
Type I interferon receptor
Anifrolumab

Phase II- recruitment completed

NCT02547922 TULIP-LN1

Phase II- recruitment completed

NCT01438489

BAFF, B-cell activating factor; BLyS, B lymphocyte stimulator